--- title: "Pre-market hot trades in US stocks: Ohmyhome pre-market down 7.63%; Lam Research pre-market up 7.34%" type: "News" locale: "en" url: "https://longbridge.com/en/news/294332428.md" description: "Ohmyhome pre-market down 7.63%; Lam Research pre-market up 7.34%; Nuwellis pre-market up 102.12%; T3 Defense pre-market up 85.19%; China Su Xuan Tang Pharmaceutical pre-market up 52.38%" datetime: "2026-07-30T09:08:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294332428.md) - [en](https://longbridge.com/en/news/294332428.md) - [zh-HK](https://longbridge.com/zh-HK/news/294332428.md) --- # Pre-market hot trades in US stocks: Ohmyhome pre-market down 7.63%; Lam Research pre-market up 7.34% **Pre-market Hot Trades in US Stocks** Ohmyhome is down 7.63% in pre-market trading. Based on recent key news: 1. On July 27, Ohmyhome announced a registered direct offering of $4 million at a price of $0.20 per share, leading to a drop in stock price. This offering involves 20 million shares of common stock, and investors can choose to purchase pre-subscription warrants at a price of $0.19, with an exercise price of $0.01. This news has raised market concerns about shareholder equity dilution, causing the stock price to drop 7.63% in pre-market trading. Source: Reuters 2. On July 27, Ohmyhome's registered direct offering was exclusively managed by Univest Securities, expected to be completed on July 28. This news further intensified market concerns about the company's short-term financial condition, impacting stock performance. Source: Public Technologies 3. No other significant news recently. Concerns about shareholder equity dilution have intensified. Lam Research is up 7.34% in pre-market trading. Based on recent key news: 1. On July 29, Lam Research reported better-than-expected fourth-quarter results and first-quarter guidance, driving the stock price up after hours. The earnings report showed a 30% year-over-year increase in fourth-quarter revenue to $6.72 billion, with adjusted earnings per share of $1.82, both exceeding analyst expectations. Looking ahead, Lam Research expects first-quarter revenue to reach $8.1 billion, with adjusted earnings per share of $2.15, both above market expectations. 2. On July 29, after the earnings report was released, at least five brokerages raised their target prices for the stock, with analysts generally optimistic about its future performance. According to LSEG data, 35 analysts have an average "buy" rating for the stock, with a median target price of $380. 3. On July 28, Lam Research benefited from increased investments related to AI, driving demand for advanced chips, which in turn boosted semiconductor equipment investments. The company is focusing on etching, cleaning, lithography, and critical film processes in the semiconductor equipment field, particularly concentrated on high aspect ratio etching/deposition and related process capabilities required for 3D NAND storage. AI-driven demand continues to reshape the semiconductor industry, with significant capital inflows. **Top Gainers in Pre-market US Stocks** Nuwellis is up 102.12% in pre-market trading. Based on recent key news: 1. On July 27, Nuwellis announced preliminary revenue results for the second quarter of 2026, showing a year-over-year increase of 14%. This growth is primarily attributed to the commercial success of the Aquadex ultrafiltration platform, driving a significant rise in stock price. 2. On July 27, Nuwellis announced a 20% year-over-year increase in preliminary revenue for the first half of 2026. This news further boosted market confidence, leading to continued stock price gains On July 27, Nuwellis plans to release its complete second-quarter financial results on August 13, with market expectations being positive, further driving up the stock price. The market remains optimistic about the prospects of the medical technology industry. T3 Defense pre-market rose 85.19%. Based on recent key news: 1. On July 29, T3 Defense rose 81.56% during the trading session, currently reported at $23.785. This sharp increase is primarily driven by both technical and fundamental factors. The company's completed 1-for-125 reverse stock split has compressed the circulating shares to 1.12 million, triggering a technical short squeeze. At the same time, the company has made operational progress and achieved contract delivery in its anti-drone technology Project 35, with strategic investment news further boosting market confidence. 2. On July 30, T3 Defense's stock price increased by 88%, currently reported at $45.12. The stock exhibits characteristics of "low circulating shares + high trading volume," making it prone to significant fluctuations. 3. On July 28, T3 Defense's stock price rose 130.76%, currently reported at $30.23. The company's subsidiary completed the delivery of an automated composite production line to a major manufacturer in Israel, while its 60% stake in Project 35 has expanded its influence in the high-demand anti-drone technology sector. SEC Schedule 13D filings show that X S.E. Security and Defense Ltd. acquired a 16.67% stake in the company, further enhancing investor interest. The demand in the defense industry is strong, and the technical short squeeze is significant. China Su Xuan Tang Pharmaceutical pre-market rose 52.38%, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation ### Related Stocks - [OMH.US](https://longbridge.com/en/quote/OMH.US.md) - [LRCX.US](https://longbridge.com/en/quote/LRCX.US.md) - [NUWE.US](https://longbridge.com/en/quote/NUWE.US.md) - [DFNS.US](https://longbridge.com/en/quote/DFNS.US.md) - [SXTC.US](https://longbridge.com/en/quote/SXTC.US.md) ## Related News & Research - [QRG Capital Management Inc. Grows Position in Lam Research Corporation $LRCX](https://longbridge.com/en/news/295912229.md) - [5 insightful analyst questions from Lam Research’s Q2 earnings call](https://longbridge.com/en/news/295375060.md) - [What's Going On With Lam Research Stock Thursday?](https://longbridge.com/en/news/295811256.md) - [Lam Research Corporation $LRCX Shares Sold by Handelsbanken Fonder AB](https://longbridge.com/en/news/295520659.md) - [Lam Research CEO Timothy Archer disposes of USD 9 million in common shares](https://longbridge.com/en/news/295262982.md)